Guidelines: From MRI use to biopsy techniques
Insights from long‑term systemic and surgical data
ESMO 2026 highlights TGCT safety data
Guidelines update: 2025 WHO Advanced HIV
A trial directly comparing Eliquis and Xarelto - two commonly used blood-thinning drugs from the same class of medicines - found that Eliquis carries a clearly lower risk of dangerous bleeding in patients with clots deep in the body, researchers reported in The New England Journal of Medicine.
In people with type 2 diabetes in the world's richest countries, deaths from cardiovascular disease are declining while mortality from dementia is on the rise, a large analysis has found.
New findings could help explain why Alzheimer's dementia often progresses faster in women and may lead to fresh avenues of research and future treatments, researchers said.
Guideline changes for inpatient IBD care
Adding a minimally invasive laser procedure to immunotherapy achieved dramatically improved survival in a small study of patients with recurrent high-grade astrocytoma, an aggressive brain cancer with few treatment options.
Insights from WORLDSymposium 2026 reveal gaps in Fabry care, from higher symptom burden to communication challenges across the patient journey.
Early enzyme therapy following newborn screening may improve motor outcomes and help stabilize disease progression in late‑onset Pompe disease.
A new blood test for the painful uterine disorder endometriosis detected cases missed by ultrasound and MRI, according to results of a study to be presented at a medical meeting this week.
Taking GLP-1 drugs for diabetes has been shown to lower the risk of adverse heart events, but a new analysis found that going off the medication – even for a few months – may increase the odds of heart attack, stroke or death.
Fake X-ray images created by artificial intelligence to resemble true results from human patients can fool not only experienced radiologists but also the AI tools themselves, according to a study that illustrates the potential for manipulation by bad actors.
Researchers have identified a biomarker linked to schizophrenia that could lead to new treatments to tackle symptoms of the debilitating mental disorder not addressed by current medicines.
